REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, ...

REDWOOD CITY, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...

-- Company to host conference call with Key Opinion Leader Dr. Arshad M. Khanani today at 1:30 pm PT / 4:30 pm ET-- REDWOOD CITY, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, ...

-The Phase 2 LUNA trial is expected to dose the first subject in the third quarter of 2022 and preliminary data anticipated throughout 2023 “We are pleased to present our findings on BCVA and CST from ...

- New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept expression through three years resulting in fluid control supporting favorable vision ...

The purpose of this study was to conduct a questionnaire-based survey of subjective visual perceptions induced by intravitreous (IVT) injections of therapeutic agents. Patients undergoing an IVT ...

The ongoing Phase 2 study includes 25 patients (16 wet AMD and 9 DME), previously treated with anti-VEGF IVT injections, and is evaluating the novel, proprietary nanomedicine, MGB, which is ...